Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)
46.45
+0.00 (0.00%)
NASDAQ · Last Trade: May 7th, 7:51 AM EDT
Via Benzinga · May 5, 2025
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.
Via Benzinga · May 5, 2025
Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS).
Via Chartmill · April 23, 2025
A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS).
Via Chartmill · April 1, 2025

Via Benzinga · January 27, 2025

The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next.
Via Investor's Business Daily · December 26, 2024

Via Benzinga · November 15, 2024

Via Benzinga · October 28, 2024

TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Via Benzinga · February 29, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via Benzinga · February 27, 2024

Via Benzinga · July 26, 2024

Has the market made its all-time highs? In this video I cover the stock and crypto markets.
Via Talk Markets · May 12, 2024

Via Benzinga · May 9, 2024

Via Benzinga · May 9, 2024

TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · February 28, 2024